Recent News
Bill Aims To Run Out the Clock on Calif. Asbestos Victims
For Immediate Release: April 23, 2015 Contact: Alex Formuzis: 202.667.6982 or alex@ewg.org Sacramento, Calif. – The EWG Action Fund has joined a growing coalition of worker, consumer, and health groups…
Public Health, Environmental Groups Push for Real Reform of U.S. Chemicals Policy
Washington, D.C. – Several public interest groups have formed a coalition to urge lawmakers to make public health the top priority as Congress debates legislation to address the serious shortfalls of the federal Toxic Substances Control…
Senators Seek Answers Regarding Asbestos in Nation’s Schools
WASHINGTON – EWG Action Fund supports Sens. Edward J. Markey (D-Mass.) and Barbara Boxer (D-Calif.) in their effort to find out how states and schools across the U.S. have implemented…
Proposal Aims to Help Americans Spot Asbestos Products
March 10, 2015 Washington, D.C. – Legislation introduced today by Sen. Richard Durbin (D-Ill) would set up a federal online database of information about products that contain asbestos and where…
Lethal and Still Legal: Asbestos Flows into U.S. Ports
New National Campaign to Raise Awareness of Continuing Threats from Asbestos March 10, 2015 Washington, D.C. – Many Americans believe asbestos was banned decades ago. But the deadly substance remains legal,…
New Congress Aligns with Asbestos Industry
Pushes for Bill on World Cancer Day that Denies Justice for Victims Contact: Monica Amarelo (202) 667-6982 press@ewgactionfund.com For Immediate Release: Wednesday, February 4, 2015 WASHINGTON – World Cancer Day should…
FACT Act Favors Asbestos Industry Over Justice, Public Health
Would waste assets meant to help victims, invade privacy and delay compensation Contact: Monica Amarelo (202) 667-6982 press@ewgactionfund.com For Immediate Release: Wednesday, January 28, 2015 WASHINGTON — Legislation re-introduced by Rep.…
Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma
Purpose: This is a phase II, monocentric study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with MPM expressing PDGFR-beta and/or C-kit by Immunohistochemistry (IHC). Treatment will be done until disease progression, or patient refusal or withdrawal of patient consent, or unacceptable toxicity.
MSB0010718C in Solid Tumors
Purpose: This is a Phase 1, open-label, dose-escalation trial of MSB0010718C [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in subjects with selected tumor indications. New recruitment has been closed for the following cohorts: non-small cell lung cancer (NSCLC), metastatic breast cancer (MBC), and metastatic colorectal cancer (mCRC).
Lung cancer is more than a smokers’ disease
The world seems to turn pink each October in honor of Breast Cancer Awareness Month, but little recognition is given to the month that follows. November marks Lung Cancer Awareness…
